Abstract: Provided herein are methods and compositions related to the administration of uricase compositions and compositions comprising synthetic nanocarriers comprising an immunosuppressant for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout.

Abstract: The present invention relates to the use of 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of anti-arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans. Furthermore, the invention concerns related methods of treatment and pharmaceutical products.

Abstract: A method of using 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans, as well as related methods and pharmaceutical products or packages.

Abstract: A method of treating or inhibiting anti-arrhythmic events in male human patients by administering to a patient in need thereof a pharmaceutically effective amount of a 3,7-diazabicyclo[3,3,1]nonane compound, preferably a 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compound, and especially preferably tedisamil, or a physiologically acceptable acid addition salt thereof or a solvate thereof. The method is particularly useful in converting recent onset of atrial fibrillation (Afib) or flutter to normal sinus rhythm (NSR) in male human patients.

Abstract: The present invention relates to the use of 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of anti-arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans. Furthermore, the invention concerns related methods of treatment and pharmaceutical products.

Abstract: The present invention relates to derivatives of piperidinedione of formula: ##STR1## in which R is alkyl or forms with N a possibly substituted morpholino or piperidino group, n=2 or 3, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 represent H or lower alkyl; R.sub.3 and R.sub.4 taken together may represent (CH.sub.2).sub.m where m=4 or 5 and R.sub.2 and R.sub.3 taken together may represent (CH.sub.2).sub.p where p=3 or 4 and in this case R.sub.1 and R.sub.4 =H, R.sub.5 is H or alkyl. It also relates to a process for manufacturing the product of formula (I) and to the drugs containing a product of formula (I).

Abstract: The present invention relates to the products of general formula: ##STR1## in which: R represents a straight or branched alkyl group having from 2 to 5 atoms of carbon, or the group ##STR2## represents a morpholino or piperidino group possibly substituted by 1 or 2 methyl groups;n=2 or 3;R.sub.1 and R.sub.2 considered independently each represent hydrogen or a lower alkyl group (1 to 4 carbon atoms) or R.sub.1 and R.sub.2 taken together represent a (CH.sub.2).sub.m group where m=4 or 5, R.sub.3 being equal to H or R.sub.1 is H and R.sub.2 and R.sub.3 considered together represent (CH.sub.2).sub.p where p is 3 or 4the butyrolactone cycle substitutes the pyridyl group in 2', 3' or 4' position,the salts, isomers and mixtures of isomers of said products; and to a process for preparing said products and to the myocardium-protecting drugs containing same.